Skip to content

Study · Measured the body's own peptide · 1996

2 results

Elcatonin raises levels of vasoactive intestinal peptide in human plasma.

Takeyama M, Ikawa K, Nagano T, Mori K

The Journal of pharmacy and pharmacology1 Jun 1996Cited by 4 (Europe PMC)

PMID8832504 (opens in a new tab)DOI10.1111/j.2042-7158.1996.tb05991.x (opens in a new tab)PepBankPUB-08832504
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialMechanism

    In five healthy volunteers, a single intramuscular dose of elcatonin raised plasma VIP, with peak levels of about 17 pg mL-1 after 30 min.

    In plain wordsIn five healthy adults, elcatonin raised the body's own VIP levels in blood.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP after elcatonin
    Study

    n = 5

    Outcome group
    Hormone levels · Endocrine and hormones

    Measurements

    Peak plasma VIP
    ≈ 17 pg mL-1
    30 min after elcatonin

    Source sentences

    Summary
    Plasma vasoactive intestinal peptide concentrations rose similarly with peak levels of about 17 pg mL-1 after 30 min.
    2 context sentences
    Summary · context
    After a single intramuscular administration of elcatonin (20 int units), peak plasma elcatonin levels (approx. 30 pg mL-1) were achieved 30 min after injection.
    Summary · context
    To determine whether this was because of increased levels of vasoactive intestinal peptide, which is known to induce vasodilation, the effect of elcatonin on the plasma levels of vasoactive intestinal peptide was studied in five healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialOther

    In five healthy volunteers, elcatonin-induced cutaneous flushing declined over 45 min in parallel with plasma VIP.

    In plain wordsIn five healthy adults, face and hand flushing after elcatonin faded at the same time as the body's own VIP level fell.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableFlushing side-effects and plasma VIP
    Study

    n = 5

    Outcome group
    Hormone levels · Endocrine and hormones

    Source sentences

    Summary
    Side-effects such as cutaneous flushing (most obvious in the face and hands) occurred to an extent dependent on the amount of elcatonin administered, and declined over 45 min in parallel with the fate of plasma vasoactive intestinal peptide.
    1 context sentence
    Summary · context
    To determine whether this was because of increased levels of vasoactive intestinal peptide, which is known to induce vasodilation, the effect of elcatonin on the plasma levels of vasoactive intestinal peptide was studied in five healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.